Survival curves of patients up to 60 years with intermediate-risk cytogenetics AML depending on NPM1 status and presence of multilineage dysplastic features (MLD). (A) In NPM1-mutated AML no significant differences in OS were observed between cases with (discontinuous line) and without (continuous line) MLD (P = .97). (B) On the contrary, MLD identified a subgroup of patients with an adverse outcome among wild-type NPM1 IR-AML (P = .012).